Valvular & structural heart disease
Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry
Authors' conclusion
In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.
Study context
- Population
- Patients undergoing surgical THV explant, EXPLANT-TAVR registry, 2011–2022
- Participants
- 372 patients
- Exposure
- THV explant for infective endocarditis (IE) vs for other bioprosthetic valve dysfunction (BVD)
- IEn = 184
- BVDn = 188reference
- Outcome
- Stroke
- Follow-up
- 30 days and 1 year
Methodological detailsinternational registry, 44 sites
- International registry
- 44 sites
Main finding
As reported in the abstract
Stroke at 30 days
P = 0.032
Stroke at 1 year
P = 0.010
- Longer ICU and hospital stays with IE
- P < 0.05
Observational data: associations, not effects.
Further findings
Mortality · 3 years postsurgery · Kaplan-Meier, not significant
P = 0.16
Adjusted mortality, entire cohort · in-hospital, 30 days, 1 year
- In-hospital mortality
- 12.1%
- 30-day mortality
- 16.1%
- 1-year mortality
- 33.8%
- No significant differences between groups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →